WallStSmart

Fresenius Medical Care Corporation (FMS)vsEverpure, Inc. (P)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 436% more annual revenue ($19.63B vs $3.66B). P leads profitability with a 5.1% profit margin vs 5.0%. FMS appears more attractively valued with a PEG of 0.75. FMS earns a higher WallStSmart Score of 62/100 (C+).

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.82

P

Buy

55

out of 100

Grade: C-

Growth: 8.0Profit: 4.0Value: 3.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+76.3%)

Margin of Safety

+76.3%

Fair Value

$101.44

Current Price

$20.19

$81.25 discount

UndervaluedFair: $101.44Overvalued

Intrinsic value data unavailable for P.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS4 strengths · Avg: 9.5/10
P/E RatioValuation
11.4x10/10

Attractively priced relative to earnings

Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
420.0%10/10

Earnings expanding 420.0% YoY

PEG RatioValuation
0.758/10

Growing faster than its price suggests

P2 strengths · Avg: 9.0/10
EPS GrowthGrowth
139.7%10/10

Earnings expanding 139.7% YoY

Revenue GrowthGrowth
20.4%8/10

Revenue surging 20.4% year-over-year

Areas to Watch

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

P4 concerns · Avg: 3.3/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

Price/BookValuation
17.0x4/10

Trading at 17.0x book value

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

P/E RatioValuation
130.2x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : P

The strongest argument for P centers on EPS Growth, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 5.0% margins leave little buffer for downturns.

Bear Case : P

The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 130.2x leaves little room for execution misses.

Key Dynamics to Monitor

FMS profiles as a value stock while P is a growth play — different risk/reward profiles.

P carries more volatility with a beta of 1.44 — expect wider price swings.

P is growing revenue faster at 20.4% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Bottom Line

FMS scores higher overall (62/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Everpure, Inc.

TECHNOLOGY · COMPUTER HARDWARE · USA

Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.

Want to dig deeper into these stocks?